Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration

Current Drug Targets

Volumn 12, Issue 2, 2011, Pages 149-172

  Becerra, E M ^a   Morescalchi, F ^b   Gandolfo, F ^b   Danzi, P ^b   Nascimbeni, G ^b   Arcidiacono, B ^b   Semeraro, F ^b  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Intraocular steroids; Intravitreal triamcinolone acetonide; Photodynamic therapy

Indexed keywords

TRIAMCINOLONE ACETONIDE; VERTEPORFIN; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; PHOTOSENSITIZING AGENT; PORPHYRIN; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; BLOOD RETINA BARRIER; DOWN REGULATION; DRUG ACTIVITY; DRUG POTENTIATION; FOLLOW UP; HEALTH CARE COST; HUMAN; LOW LEVEL LASER THERAPY; MONOTHERAPY; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; REVIEW; SUBRETINAL NEOVASCULARIZATION; TACHYPHYLAXIS; TREATMENT PLANNING; UVEITIS; VISUAL ACUITY; VITREORETINOPATHY; ANIMAL; BLINDNESS; DELAYED RELEASE FORMULATION; DRUG ANTAGONISM; EXUDATIVE MACULAR DEGENERATION; HYPERTHERMIC THERAPY; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLINDNESS; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; HUMANS; HYPERTHERMIA, INDUCED; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTORS; WET MACULAR DEGENERATION;

EID: 79955667358     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011794182746     Document Type: Review

References (178)

1. Lassota N. Clinical and histological aspects of CNV formation: studies in an animal model. Acta Ophthalmol 2008; 86: 1-24.
2. Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009; 116: S1-7.
3. Chen H, Liu B, Lukas TJ, Neufeld AH. The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration. PLoS One 2008; 3(6): e2339.
4. Miller DW, Joussen AM, Holz FG. The molecular mechanisms of neovascular age-related macular degeneration. Ophthalmologe 2003; 100(2): 92-6.
5. Yang P, Tyrrell J, Han I, Jaffe GJ. Expression and modulation of RPE cell membrane complement regulatory proteins. Invest Ophthalmol Vis Sci 2009; 50(7): 3473-81.
6. Richards A, Kavanagh D, Atkinson JP. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007; 96: 141-77.
7. Nussenblatt RB, Liu B, Li Z. Age-related macular degeneration: an immunologically driven disease. Curr Opin Investig Drugs 2009; 10: 434-42.
8. Patel S. Combination therapy for age-related macular degeneration. Retina 2009; 29: S45-8.
9. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982; 100: 912-8.
10. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1990; 108: 816-24.
11. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Arch Ophthalmol 1999; 117: 1329-45.
12. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198-207.
13. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina 2000; 20: 325-30.
14. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-60.
15. Blinder KJ, Bradley S, Bressler NM, et al. Treatment of Agerelated Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136: 407-18.
16. Sharma S, Brown GC, BrownMM, Holland H, Shah GK. The cost effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularisation secondary to age related macular degeneration. Ophthalmology 2001; 108: 2051-9.
17. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 103: 708-11.
18. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001; 119: 399-404.
19. Ciulla TA, Criswell MH, Danis RP, et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol 2003; 87: 1032-7.
20. Penfold PL, Gyory J, Hunyor A, Billson FA. Exudative macular degeneration and triamcinolone: a pilot study. Aust N Z J Ophthalmol 1995; 23: 293-8.
21. Challa JK, Gilles MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow-up. Aust N Z J Ophthalmol 1998; 26: 277-81.
22. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002; 86: 527-9.
23. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-50.
24. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003; 87: 462-8.
25. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004; 122: 218-22.
26. Jonas JB, Spandau UH, Harder B, Vossmerbaeumer U, Kamppeter BA. Inter-eye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2005; 139: 1073-9.
27. Jonas JB, Kreissig I, Degenring RF. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration. Br J Ophthalmol 2004; 88: 1557-62.
28. Jonas JB, Degenring RF, Kressig I, Friedmann T, Akkoyun I. Exudative age related macular degeneration treated by intravitreal triamcinolone acetonide: a prospective comparative nonrandomized study. Eye 2005; 19: 163-70.
29. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 121: 667-73.
30. Gilles MC, Larsson J. The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration. Am J Ophthalmol 2007; 144: 134-6.
31. Lee J, Freeman WR, Azen SP, Chung EJ, Koh HJ. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina 2007; 27: 1205-13.
32. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
33. Jonas JB, Ihloff AK, Harder B, et al. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic Res 2009; 41: 21-7.
34. Costa RA, Farah ME, Cardillo JA, Calucci D, Williams GA. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 2000; 23: 159-65.
35. Ferrario A, von Tiehl KF, Rucker N, et al. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammari carcinoma. Cancer Res 2000; 60: 4066-9.
36. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-80.
37. Schnurrbusch UE, Jochmann C, Einbock W et al Complications of photodynamic therapy. Arch Ophthalmol 2005; 123: 1347-1350.
38. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-25.
39. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301-4.
40. Arevalo JF, Garcia RA, Mendoza AJ. Indocyanine green-mediated photothrombosis with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005; 243: 1180-5.
41. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 14-22.
42. Iwama D, Otani A, Sasahara M, et al. Photodynamic therapy combined with low-dose intravitreal triamcinolone acetonide for age-related macular degeneration refractory to photodynamic therapy alone. Br J Ophthalmol 2008; 92: 1352-6.
43. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004; 88: 344-7.
44. Axer-Siegel R, Ehrlich R, Avisar I, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging 2006; 37: 455-61.
45. Ergun E, Maár N, Ansari-Shahrezaei S, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 2006; 142: 10-16.
46. Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006; 90: 337-41.
47. Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative agerelated macular degeneration: 2-year outcome. Retina 2007; 27: 458-61.
48. Ruiz-Moreno JM, Montero JA, Barile S. Triamcinolone and PDT to treat exudative age-related macular degeneration and submacular hemorrhage. Eur J Ophthalmol 2006; 16: 426-34.
49. Arias L, Garcia-Arumi J, Ramon JM, et al. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 2006; 113: 2243-50.
50. Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Optical coherence tomography analysis of a randomized study combining photodynamic therapy with intravitreal triamcinolone. Graefes Arch Clin Exp Ophthalmol 2008; 246: 245-54.
51. Gamulescu MA, Schubert K, Thormann S, et al. ITAP-6-month results of a prospective, randomized phase 3 study for evaluation of the combination therapy of PDT and intravitreal triamcinolone in exudative AMD. Klin Monatsbl Augenheilkd 2009; 226: 60-5.
52. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141: 638-45.
53. Nicolò M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G. Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 2006; 26: 58-64.
54. Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular agerelated macular degeneration: a prospective randomized trial. Ophthalmology 2007; 114: 2183-9.
55. Lee YA, Ho TC, Chen MS, Yang CH, Yang CM. Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization. Eye 2009; 23: 645-51.
56. Montero JA, Ruiz-Moreno JM, Sanabria MR, Fernandez-Munoz M. Efficacy of intravitreal and periocular triamcinolone associated with photodynamic therapy for treatment of retinal angiomatous proliferation. Br J Ophthalmol 2009; 93: 166-70.
57. Iriyama A, Obata R, Inoue Y, Takahashi H, Tamaki Y, Yanagi Y. Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 339-44.
58. Ishikawa K, Nishihara H, Ozawa S, et al. Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide. Retina 2009; 29: 803-10.
59. Van de Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 2005; 112: 1896-903.
60. Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy (NAPP) Trial Research Group, Gilson MM, Bressler NM, Jabs DA, Solomon SD, Thorne JE, Wilson DJ. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 2007; 114: 1713-21.
61. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995; 120: 55-64.
62. Weber U, Hecker H. Transpupillary thermotherapy for occult choroidal neovascularizations. Ophthalmologe 2005; 102: 355-62.
63. Zhang X, Zhu X, Wang D, Xu L, Jonas JB. Low-power transpupillary thermotherapy combined with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization. Ophthalmic Res 2007; 39: 241-2.
64. Agurto-Rivera R, Diaz-Rubio J, Torres-Bernal L, et al. Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]. BMC Ophthalmol 2005; 5: 27.
65. Lo Giudice G, De Belvis V, Piermarocchi S, Galan A, Prosdocimo G. Acute visual loss and chorioretinal infarction after photodynamic therapy combined with intravitreal triamcinolone. Eur J Ophthalmol 2008; 18: 652-5.
66. Blaha GR, Wertz FD 3rd, Marx JL. Profound choroidal hypoperfusion after combined photodynamic therapy and intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2008; 39: 6-11.
67. Luttrull JK, Spink CJ. Prolongation of choroidal hypofluorescence following combined verteporfin photodynamic therapy and intravitreal triamcinolone acetonide injection. Retina 2007; 27: 688-92.
68. Piermarocchi S, Sartore M, Lo Giudice G, Maritan V, Midena E, Segato T. Combination of photodynamic therapy and intraocular triamcinolone for exudative age-related macular degeneration and long-term chorioretinal macular atrophy. Arch Ophthalmol 2008; 126: 1367-74.
69. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006; 47: 371-6.
70. Singh CN, Saperstein DA. Combination treatment with reducedfluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 2008; 28: 789-93.
71. Hahn R, Sacu S, Michels S, et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration Ophthalmologe 2007; 104: 588-93.
72. Sacu S, Varga A, Michels S, et al. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomized study. Br J Ophthalmol 2008; 92: 1347-51.
73. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
74. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
75. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372. e5.
76. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-90.
77. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina 2006; 26: 495-511.
78. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1-9.
79. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomized, controlled clinical study. Br J Ophthalmol 2008; 92: 356-60.
80. Sacu S, Michels S, Prager F, et al. Randomized clinical trial of intravitreal Avastin vs. photodynamic therapy and intravitreal triamcinolone: long-term results. Eye 2009; 23: 2223-7.
81. Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye. 2009; 23: 2163-8.
82. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-248.
83. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-83.
84. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008; 115: 2199-205.
85. Colucciello M. Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular agerelated macular degeneration: short-term optical coherence tomography results. J Ocul Pharmacol Ther 2008; 24: 15-24.
86. Jonas JB, Libondi T, Golubkina L, et al. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. Acta Ophthalmol 2009; Apr 27.
87. Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006; 142: 1072-4.
88. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-40.
89. Ahmadieh H, Taei R, Soheilian M, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 2007; 7: 10.
90. Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol 2009; 93: 754-8.
91. Yannuzzi LA, Negrão S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21: 416-34.
92. Axer-Siegel R, Bourla D, Priel E, Yassur Y, Weinberger D. Angiographic and flow patterns of retinal choroidal anastomoses in age-related macular degeneration with occult choroidal neovascularization. Ophthalmology 2002; 109: 1726-36.
93. Krebs I, Stolba U, Glittenberg C, et al. Prognosis of untreated occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007; 245: 376-84.
94. Sakimoto S, Gomi F, Sakaguchi H, Tano Y. Recurrent retinal angiomatous proliferation after surgical ablation. Am J Ophthalmol 2005; 139: 917-8.
95. Borrillo JL, Sivalingam A, Martidis A, Federman JL. Surgical ablation of retinal angiomatous proliferation. Arch Ophthalmol 2003; 121: 558-61.
96. Bottoni F, Massacesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol 2005; 123: 1644-50.
97. Krieglstein TR, Kampik A, Ulbig M. Intravitreal triamcinolone and laser photocoagulation for retinal angiomatous proliferation. Br J Ophthalmol 2006; 90(11): 1357-60.
98. Roth DB, Scott IU, Gloth JM, et al. Micropulsed laser photocoagulation and intravitreal triamcinolone acetonide injection for the treatment of retinal angiomatous proliferation. Retina 2007; 27: 1201-4.
99. Boscia F, Furino C, Prascina F, et al. Combined surgical ablation and intravitreal triamcinolone acetonide for retinal angiomatous proliferation. Eur J Ophthalmol 2005; 15: 513-6.
100. Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1224-32.
101. Freund KB, Klais CM, Eandi CM, et al. Sequenced combined intravitreal triamcinolone and indocyanine green angiographyguided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 2006; 124: 487-92.
102. Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. Eur J Ophthalmol 2006; 16: 705-10.
103. van de Moere A, Kak R, Sandhu SS, Talks SJ. Anatomical and visual outcome of retinal angiomatous proliferation treated with photodynamic therapy and intravitreal triamcinolone. Am J Ophthalmol 2007; 143: 701-4.
104. Bottoni F, Romano M, Massacesi A, Bergamini F. Remodeling of the vascular channels in retinal angiomatous proliferations treated with intravitreal triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1528-33.
105. Krebs I, Krepler K, Stolba U, Goll A, Binder S. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT vs. PDT alone. Graefes Arch Clin Exp Ophthalmol 2008; 246: 237-43.
106. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, et al. Retinal angiomatous proliferation reactivation 6 months after high-dose intravitreal acetonide triamcinolone and photodynamic therapy. Eur J Ophthalmol 2007; 17: 979-82.
107. Sutter FK, Kurz-Levin MM, Fleischhauer J, et al. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klin Monatsbl Augenheilkd 2006; 223: 376-8.
108. Costagliola C, Romano MR, dell'Omo R, Cipollone U, Polisena P. Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation. Am J Ophthalmol 2007; 144: 449-51.
109. Rouvas AA, Papakostas TD, Vavvas D, et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina 2009; 29: 536-44.
110. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110: 681-6.
111. Inoue M, Takeda K, Morita K, Yamada M, et al. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 2004; 138: 1046-8.
112. Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 2002; 86: 1450-1.
113. Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 2000; 121: 458-65.
114. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002; 240: 42-8.
115. Hollborn M, Stathopoulos C, Steffen A, et al. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci 2007; 48: 4360-7.
116. Penfold PL, Wen L, Madigan MC, King NJ, Provis JM. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002; 43: 3125-30.
117. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980; 90: 810-6.
118. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 89-96.
119. Kato A, Kimura H, Okabe K, et al. Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide. Retina 2005; 25: 503-9.
120. Spandau UH, Sauder G, Schubert U, Hammes HP, Jonas JB. Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br J Ophthalmol 2005; 89: 745-7.
121. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGFinduced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005; 80: 249-58.
122. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341: 309-15.
123. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005; 46: 1062-8.
124. Itaya H, Imaizumi T, Yoshida H, et al. Expression of vascular endothelial growth factor in human monocyte/macrophages stimulated with lipopolysaccharide. Thromb Haemost 2001; 85: 171-6.
125. Li YH, Brauner A, Jensen JS, Tullus K. Induction of human macrophage vascular endothelial growth factor and intercellular adhesion molecule-1 by Ureaplasma urealyticum and downregulation by steroids. Biol Neonate 2002; 82: 22-8.
126. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004; 122: 1801-7.
127. Tatar O, Adam A, Shinoda K, et al. Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2009; 127: 275-81.
128. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986; 101: 190-5.
129. Lorenzo Carrero J, González Barcia M, Pérez Flores I. Sterile endophthalmitis after benzyl alcohol filtered triamcinolone acetonide injection. Arch Ophthalmol 2008; 126: 142-3.
130. Yeung CK, Chan KP, Chiang SW, Pang CP, Lam DS. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 2003; 44: 5293-300.
131. Baath J, Ells AL, Crichton A, Kherani A, Williams RG. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2007; 23: 304-10.
132. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004; 138: 158-60.
133. Du L, Xing Y, Chen C. Filter connected with three-way cock in remove of the vehicle in triamcinolone acetonide. Yan Ke Xue Bao 2006; 22: 156-65.
134. Rodriguez-Coleman H, Yuan P, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004; 122: 1085-6.
135. Ober MD, Barile GR, Tari SR, et al. Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection. Am J Ophthalmol 2006; 142: 597-600.
136. García-Arumí J, Boixadera A, Giralt J, et al. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol 2005; 89: 1112-4.
137. Pece A, Introini U, Bottoni F, Brancato R. Acute retinal pigment epithelial tear after photodynamic therapy. Retina 2001; 21: 661-5.
138. Sutter FK, Kurz-Levin MM, et al. Intravitreal triamcinolone acetonide for serous retinal pigment epithelial detachments in exudative age-related macular degeneration. Klin Monatsbl Augenheilkd 2007; 224: 297-9.
139. Roth DB, Kulkarni KM, Feuer WJ. The temporal sequence of combined intravitreal triamcinolone acetonide and photodynamic therapy for exudative age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2008; 39: 12-6.
140. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 1980; 89: 131-6.
141. Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in aqueous humour. Br J Ophthalmol 2002; 86: 1066.
142. Bergh F, Grasser A, Trenkwalder C, et al. Binding characteristics of the glucocorticoid receptor in peripheral blood lymphocytes in multiple sclerosis. J Neurol 1999; 246: 292-8.
143. Han D, Ogita K, Kashiwai K, Narita S, Yoneda Y. Binding of triamcinolone acetonide to glucocorticoid receptors in brain cytosol fractions of rats with intact adrenals. Neurochem Int 1994; 24: 339-48.
144. Frimpong-Boateng A, Bunse A, Rüfer F, Roider J. Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: functional results in 54 patients. Acta Ophthalmol 2009; 87: 183-7.
145. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004; 24: 676-98.
146. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136: 791-6.
147. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 23: 686-91.
148. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006; 141: 579-80.
149. Roth DB, Chieh J, Ppirn MJ, et al. Non infectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121: 1279-82.
150. Moshfeghi AA, Scott IU, Flynn HW Jr, Puliafito CA. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004; 138: 489-92.
151. Chen SD, Lochhead J, McDonald B, Patel CK. Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br J Ophthalmol 2004; 88: 843-4.
152. Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 2008; 28(7): 996-1001.
153. Johnson D, Gottanka J, Flügel C, Hoffmann F, Futa R, Lütjen-Drecoll E. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol 1997; 115: 375-83.
154. Kubota T, Okabe H, Hisatomi T, Yamakiri K, Sakamoto T, Tawara A. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006; 15: 117-9.
155. Tektas OY, Lütjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res 2009; 88: 769-75.
156. Tammewar AM, Cheng L, Kayikcioglu OR, et al. Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections. Br J Ophthalmol 2008; 92: 810-3.
157. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1412-9.
158. Scott IU, Ip MS, VanVeldhuisen PC, et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-28.
159. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-8.
160. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006; 90: 999-1003.
161. Jonas JB, Schlichtenbrede F. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye 2008; 22: 869-73.
162. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006; 17: 163-7.
163. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina 2008; 28: 573-80.
164. Ruiz-Moreno JM, Montero JA, Amat P, Lugo FL. Secondary elevated IOP and cataracts after high-dose intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization. J Glaucoma 2009; 18: 69-72.
165. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122: 336-40.
166. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533-8.
167. Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009; 116: 902-11.
168. Mueller AJ, Jian G, Banker AS, et al. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther 2009; 25: 159-62.
169. Mueller AJ, Jian G, Banker AS, Rahhal FM, Capparelli E, Freeman WR. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol 1998; 125: 158-63.
170. Islam MS, Vernon SA, Negi A. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years. Eye 2007; 21: 321-3.
171. Cekiç O, Chang S, Tseng JJ, Akar Y, Barile GR, Schiff WM. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005; 139: 993-8.
172. Jonas JB, Degenring R, Vossmerbauemer U, Kamppeter B. Frequency of cataract surgery after intravitreal injection of highdosage triamcinolone acetonide. Eur J Ophthalmol 2005; 15: 462-4.
173. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005; 112: 139-43.
174. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006; 141: 629-37.
175. Mansoor S, Kuppermann BD, Kenney MC. Intraocular sustainedrelease delivery systems for triamcinolone acetonide. Pharm Res 2009; 26: 770-84.
176. Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115: 1039-45.
177. Smiddy WE. Economic implications of current age-related macular degeneration treatments. Ophthalmology 2009; 116: 481-7.
178. Larsson J, Gillies MC. Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration. Clin Exp Ophthalmol 2005; 33: 544-5.